Cardiogen
A synthetic tetrapeptide (Ala-Glu-Asp-Arg) from the Khavinson bioregulator family, studied for cardiovascular tissue bioregulation and cardiac geroprotection.
Also referenced as: AEDR, Ala-Glu-Asp-Arg
Also appears in: Longevity
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when Cardiogen crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Cardiovascular. Also surfaces under Longevity for browsing and discovery.
AEDR, Ala-Glu-Asp-Arg
FDA label signal · 4 trials · 44 PubMed results
Current evidence for Cardiogen is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
Cardiogen has 1 name-matched clinical trial (highest phase: no phased trial) and 44 PubMed-indexed publications and is not FDA-approved. Note: 1 retracted publication in the literature.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-17 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Cardiogen?
Cardiogen is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Arg (AEDR), developed as part of the Khavinson bioregulator peptide program. It is classified as a cardiovascular-tissue bioregulator, theorized to support cardiac and vascular function through tissue-specific gene modulation.
How it works
- Cardiac gene regulation — short peptides are proposed to modulate gene expression in cardiac tissue, supporting myocardial function in aging (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
- Vascular support — the peptide is theorized to interact with endothelial cell DNA to maintain vascular integrity, though specific gene targets remain uncharacterized in Western literature
Research status
- Khavinson (2005) reviewed cardiovascular applications of peptide bioregulators (Gerontology, 51(2):70–75)
- Anisimov et al. (2003) reported broader geroprotective effects of bioregulator peptide preparations (Annals of the New York Academy of Sciences, 992:141–147)
- No specific Western peer-reviewed clinical trials for Cardiogen have been published
Key considerations
- Part of the Khavinson bioregulator family — same research group and proposed mechanism as other organ-specific peptides
- Limited independent replication outside the originating research group
- Available from research vendors as lyophilized powder or capsules (typically 10–20mg)
- Often sold in combination packs with other Khavinson bioregulators